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Previous studies have suggested that prior exposure to hepatitis B virus (HBV) infection may
increase the risk of development of hepatocellular carcinoma (HCC) in patients with chronic
hepatitis C. The aim of this study was to compare the prevalence of previous or occult HBV
infection in a cohort of hepatitis B surface antigen–negative patients with histologically
advanced chronic hepatitis C in the United States who did or did not develop HCC. Stored
sera from 91 patients with HCC and 182 matched controls who participated in the Hepatitis
C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial were tested for hepatitis
B core antibody (anti-HBc), hepatitis B surface antibody, and HBV DNA. Frozen liver sam-
ples from 28 HCC cases and 55 controls were tested for HBV DNA by way of real-time poly-
merase chain reaction. Anti-HBc (as a marker of previous HBV infection) was present in the
serum of 41.8% HCC cases and 45.6% controls (P5 0.54); anti-HBc alone was present in
16.5% of HCC cases and 24.7% of controls. HBV DNA was detected in the serum of only
one control subject and no patients with HCC. HBV DNA (as a marker of occult HBV infec-
tion) was detected in the livers of 10.7% of HCC cases and 23.6% of controls (P5 0.18).
Conclusion: Although almost half the patients in the HALT-C Trial had serological evidence
of previous HBV infection, there was no difference in prevalence of anti-HBc in serum or
HBV DNA in liver between patients who did or did not develop HCC. In the United States,
neither previous nor occult HBV infection is an important factor in HCC development
among patients with advanced chronic hepatitis C. (HEPATOLOGY 2011;54:434-442)
H
epatitis B virus (HBV) infection is marked by
the presence of hepatitis B surface antigen
(HBsAg) in serum. Clearance of HBsAg indi-
cates recovery from infection; however, low levels of
HBV DNA may persist within the liver and occasion-
ally in the serum, indicating that infection is not
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totally resolved in some patients. The presence of
HBV DNA in HBsAg-negative persons has been
referred to as ‘‘occult’’ HBV infection. It has been sug-
gested that occult HBV infection may contribute to
ongoing liver disease and the development of hepato-
cellular carcinoma (HCC).1-3 There is evidence that
previous HBV infection, marked only by the presence
of antibodies to HBV—notably hepatitis B core anti-
body (anti-HBc) with or without hepatitis B surface
antibody (anti-HBs)—may also indicate persistent
HBV infection. Previous HBV infection has also been
linked with progressive liver disease, particularly as a
cofactor among patients with another form of underly-
ing liver disease such as chronic hepatitis C or alco-
holic liver disease.
Prior studies have shown that the prevalence of
occult HBV infection is higher in countries where
HBV infection is prevalent, in patients with serologi-
cal markers of previous HBV infection, and in
patients who have risk factors for HBV infection
such as those with human immunodeficiency virus or
hepatitis C virus (HCV) infection. What remains
uncertain is the clinical significance of low-level, per-
sistent HBV infection, especially among patients with
another cause of liver disease. Several studies, mostly
from Europe and Japan, have found a higher rate
of occult HBV infection in patients with chronic
HCV infection who have HCC compared with
HCV-infected patients with no HCC.1-4 In some of
these studies, the prevalence of occult HBV infection
in HCV patients with HCC was as high as 60%-
70%.2-4 However, data on the prevalence of occult
HBV infection in HCV patients and the contribution
of occult HBV to HCC in the United States are
limited.
The Hepatitis C Antiviral Long-term Treatment
against Cirrhosis (HALT-C) Trial prospectively fol-
lowed patients with chronic HCV infection and
advanced hepatic fibrosis for clinical outcomes includ-
ing HCC. All the patients tested negative for HBsAg
in the serum at enrollment. This large cohort provides
an excellent opportunity to study the clinical signifi-
cance of previous or occult HBV infection in patients
with chronic HCV infection in the United States. The
aims of this analysis were to compare the prevalence of
previous and occult HBV infection in HALT-C
patients who developed HCC and those who did not
develop HCC. In addition, we assessed the demo-
graphics, risk factors for HCV infection, and labora-
tory and histological indicators of liver disease in
HALT-C patients with and without previous and
occult HBV infection.
Patients and Methods
The design of the HALT-C Trial has been
described.5,6 Briefly, patients with chronic hepatitis C
had to meet the following criteria for enrollment: fail-
ure to achieve sustained virological response after pre-
vious interferon treatment with or without ribavirin,
presence of advanced hepatic fibrosis on liver biopsy
(Ishak fibrosis score 3), no history of hepatic decom-
pensation or HCC, and absence of defined exclusion
criteria. Specifically, patients who were positive for
HBsAg or human immunodeficiency virus antibody
were excluded from the trial.
All patients were required to undergo a liver biopsy
before enrollment. For those in whom the entry biopsy
was performed subsequent to consent into the HALT-
C Trial, a portion of the biopsy was snap-frozen and
stored for future research after an adequate specimen
was allocated for histologic assessment. The biopsy
specimens were initially stored at 70C at the clinical
sites and then sent to a central repository (SeraCare
Life Sciences, Gaithersburg, MD) on dry ice. Upon
arrival at the central repository, the specimens were
stored in 70C freezers with backup generators.
All patients had been treated previously for chronic
hepatitis C with one or more courses of interferon,
with the most recent course being a combination of
peginterferon and ribavirin. Patients who remained
viremic during treatment or experienced viral break-
through or relapse after initial response were random-
ized to maintenance therapy (peginterferon alfa-2a 90
lg/week) or to no further treatment for the next 3.5
years. Following completion of the 3.5 years of the
randomized trial, all patients were invited to continue
follow-up without treatment.
At entry, all patients were required to undergo ultra-
sound, computed tomography, or magnetic resonance
imaging examination with no evidence of hepatic mass
lesions suspicious for HCC and to have an alpha-feto-
protein (AFP) <200 ng/mL.
Patients were scheduled to be seen every 3 months
during the 3.5 years of the randomized trial and every
6 months thereafter. At each visit, patients were eval-
uated clinically and blood tests were performed. Blood
samples for research were collected on site and then
centrifuged; sera were initially stored at 70C at the
clinical sites and periodically sent on dry ice to Sera-
Care where they were stored in 70C freezers with
backup generators. Protocol-defined ultrasound exami-
nation was performed at intervals of 6-12 months.5,6
Patients with elevated or rising AFP and those with
new lesions on ultrasound examination were further
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evaluated by way of computed tomography or mag-
netic resonance imaging.
Two definitions of HCC, one for presumed and one
for definite, have been published.7 Definite HCC was
defined by histology or a new mass on imaging with
AFP levels increasing to 1,000 ng/mL. Presumed
HCC was defined as a new mass on ultrasound in
conjunction with two liver imaging studies showing a
lesion with characteristics of HCC or evidence of pro-
gression on follow-up. All cases of HCC were reviewed
by an Outcomes Review Panel comprised of panels of
three clinical investigators.
To compare the prevalence of previous and occult
HBV infection, a case-control study was performed.
All HCC cases (definite or presumed) diagnosed at
any time after enrollment into the HALT-C Trial were
studied. Two controls were selected for each case of
HCC, matched for fibrosis stratum on baseline biopsy
(Ishak score 3 or 4 versus 5 or 6), treatment assign-
ment (peginterferon versus no treatment for random-
ized patients), and duration of follow-up. To ensure
that control subjects did not harbor early HCC, they
were required to be followed for at least 12 months af-
ter the date of their matching with the HCC patient,
and to not have HCC at any time during the HALT-
C Trial.
Previous HBV infection was defined as the presence
of anti-HBc with or without anti-HBs or HBV DNA
in serum. Occult HBV infection was defined as the
presence of HBV DNA in the liver.
HBV Markers in Serum. All patients tested nega-
tive for HBsAg in the clinical laboratory at the local
HALT-C site prior to their enrollment into the HALT-
C Trial. Stored serum samples were coded and sent to
the clinical laboratory at University of California,
Irvine, where they were tested for anti-HBc (ETI-AB-
COREK PLUS; DiaSorin Inc., Stillwater, MN) and
anti-HBs (ADVIA Centaur anti-HBs; Siemens Health-
care Diagnostics, Inc., Tarrytown, NY) by way of
enzyme immunoassay (anti-HBc) or chemiluminescent
immunoassay (anti-HBs). Serum HBV DNA was
tested by way of real-time polymerase chain reaction
(PCR) assay (COBAS TaqMan HBV Test; Roche
Diagnostics, Indianapolis, IN) with a lower limit of
quantification of 30 IU/mL and a lower limit of detec-
tion of 10 IU/mL.
HBV DNA in Liver. Frozen liver samples from the
HCC cases and selected controls, where available, were
coded and tested for the presence of HBV DNA at
the University of Michigan in the laboratory of one of
the authors (A. S. F. L.). DNA was extracted from
liver biopsies using the QIAamp DNA mini kit (QIA-
GEN, Valencia, CA) and HBV DNA was quantified
by way of real-time PCR assay, as described.8 Each
sample was tested in duplicate with two sets of primers
and probes (Supporting Table 1), one spanning nucle-
otide positions 1167-1283 in the HBV polymerase
gene and the other nucleotide positions 333-476 in
the HBV surface gene (that overlaps with the polymer-
ase gene). To monitor for contamination during each
step, sterile double-distilled water and liver specimens
from uninfected persons (liver donors who were
HBsAg-negative and anti-HBc–negative with undetect-
able HBV DNA in serum by way of PCR assay) were
used as negative controls. Each assay also included
explant liver from an HBsAg-positive patient who was
previously demonstrated to have detectable hepatic
HBV DNA as a positive control. Quantification of
b-actin was used to estimate the amount of genomic
DNA and the number of hepatocytes in each liver
sample, and the amount of HBV DNA was expressed
as IU/cell. The lower limit of detection of the assay
was 5 IU/mL.8
To verify reproducibility of the assay results, six of
54 samples with negative results in all four PCR reac-
tions and two of 10 samples with positive results in all
four PCR reactions were retested, and all samples
showed 100% concordance on retesting. All 22 sam-
ples with positive results in one to three PCR reactions
were retested, and only samples with positive results in
at least six of eight PCR reactions (i.e., positive results
with both sets of primers) were considered positive.
Statistical Analyses. Descriptive statistics were
reported as number and percent or mean and standard
deviation. Baseline characteristics and HBV markers of
HCC cases and matched controls were compared with
conditional logistic regression for matched pairs. Con-
trols were excluded if data were not available for their
case. All analyses were performed at the data coordi-
nating center (New England Research Institutes,
Watertown, MA) using SAS statistical software version
9.2 (SAS Institute, Cary, NC). A two-sided signifi-
cance level of 5% was used for all analyses.
Results
Ninety-one HCC cases (definite and presumed) and
182 matched controls were included in this study.
Among the HCC cases, three were diagnosed during
the lead-in phase of HALT-C, one after achieving a
sustained virologic response, and the remaining 87
were nonresponders. In the latter group, HCC was
diagnosed a median of 4.2 years (range, 0.2-8.5 years)
after randomization. In comparing HCC cases and
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controls, those with HCC were older and more likely
to have characteristics of more advanced liver disease,
including lower platelet counts, lower serum albumin
levels, and higher bilirubin levels, and more frequently
had varices (Table 1). Risk factors for HCV infection,
estimated duration of HCV infection, alcohol con-
sumption, and history of smoking were not different
between HCC cases and controls.
Frozen liver samples were available from 28 of 91
(30.8%) HCC cases and from 55 of 182 (30.2%) con-
trols. Patients (HCC cases and controls) with liver
samples were similar to those without liver samples
regarding demographics, severity of liver disease, fibro-
sis stage, and treatment assignment. Among those with
liver samples, the baseline characteristics of the cases
and controls were similar except for lower serum albu-
min levels in the HCC cases.
HBV Markers in Serum. Almost half of the
patients had evidence of previous HBV infection; thus
38 of 91 (41.8%) HCC cases and 83 of 182 (45.6%)
controls had anti-HBc detectable in their serum (Fig.
1, Table 2). Of these, 15 (16.5%) HCC cases and 45
(24.7%) controls had isolated anti-HBc (without anti-
HBs). Compared with patients who were seronegative
for anti-HBc, the odds ratio (OR) and 95% confi-
dence interval (CI) for HCC development was OR
0.85 (95% CI 0.51-1.43) for those who were anti-
HBc positive (with or without anti-HBs) and OR 0.63
Table 1. Baseline Characteristic of HCC Cases and Controls
HCC (n 5 91) No HCC (n 5 182) P Value*
Demographics
Age, years 52.8 (7.42) 50.3 (7.26) 0.01
Male sex 75.8% 73.6% 0.70
Race





HCV genotype 1 91.2% 96.1% 0.09
Log HCV RNA (IU/mL) 6.37 (0.51) 6.47 (0.52) 0.16
Duration of HCV infection, years 30.7 (8.79) 27.7 (8.19) 0.01
Laboratory tests
Platelets 1,000/mm3 126.3 (49.2) 162.0 (61.5) <0.0001
Albumin, g/dL 3.73 (0.39) 3.87 (0.45) 0.02
AST, U/L 112.0 (63.3) 91.3 (68.0) 0.02
ALT, U/L 128.2 (90.6) 110.0 (88.9) 0.13
Alkaline phosphatase, U/L 118.0 (57.7) 103.3 (50.9) 0.04
Total bilirubin, mg/dL 0.90 (0.44) 0.81 (0.39) 0.10
INR 1.09 (0.12) 1.04 (0.11) 0.002
AFP, ng/mL 27.5 (31.6) 14.4 (24.5) 0.002
Liver histology*
Cirrhosis 56.0% 55.5% 0.99
Fibrosis 44.0% 44.5%
Treatment assignment
Maintenance peginterferon 42.5% 46.7% 0.99
Control 57.5% 53.3%
Smoking/Alcohol
Ever smoked 82.4% 75.3% 0.20
Lifetime no. of drinks 18,725 (23,756) 20,610 (36,424) 0.65
Portal hypertension
Esophageal varices on endoscopy 43.5% 28.0% 0.02
Hepatitis C risk factors
Transfusion of blood or blood products 43.3% 38.7% 0.44
Occupational exposure to human blood 24.4% 24.2% 0.92
Tattoos 28.6% 32.4% 0.51
Body piercing 0.0% 1.6% 0.99
Recreational drug use 44.0% 44.5% 0.93
Cocaine use 51.7% 56.0% 0.47
Data are expressed as the mean (SD) or as a percentage. Controls were matched on fibrosis stage, treatment assignment, and duration of follow-up.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio. Bold type indicates statistical significance.
*Determined by way of conditional logistic regression analysis.
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(95% CI 0.33-1.12) for those who were anti-HBc–
alone positive. The OR was similar when only patients
with definite HCC were evaluated.
HBV DNA was detected in the serum of only one
(0.4%) patient. This was a control subject with iso-
lated anti-HBc. Serum HBV DNA level was very low
(<30 IU/mL), but HBV DNA was detected in the
liver
HBV DNA in Liver. Three of 28 (10.7%) HCC
cases and 13 of 55 (23.6%) controls had HBV DNA
detectable in the liver (Fig. 2). Compared with the
patients with no detectable HBV DNA in the liver,
those with HBV DNA in the liver had a matched OR
of 0.42 (95% CI 0.12-1.52; P ¼ 0.18) for HCC de-
velopment (Table 2). The mean 6 SD HBV DNA
concentrations in the cases and controls were 0.0047
6 0.0056 and 0.0267 6 0.0602 IU/cell, respectively.
Two of the three (66.7%) HCC cases and eight of 13
(61.5%) controls with HBV DNA in the liver were
anti-HBc–positive in serum; of these, one HCC case
and four controls had isolated anti-HBc.
Characteristics of Patients with and Without
HBV Markers. Compared with patients who were
anti-HBc–negative, those who were anti-HBc–positive
were more likely to have a history of injection drug
use and/or a history of snorting cocaine and less likely
to have a history of blood transfusion; anti-HBc–posi-
tive patients also were shown to have lower serum al-
bumin levels (Table 3). Patients who were anti-HBc–
positive were also more likely to have a history of
being tattooed and a history of body piercing and to
be black than patients who were anti-HBc–negative,
although these differences were not significant. Stage
of hepatic fibrosis, presence of esophageal varices, and
estimated duration of HCV infection were similar
between those with and without anti-HBc.
Patients with and without HBV DNA in the liver
were similar with regard to demographics, baseline lab-
oratory values, fibrosis stage, presence of esophageal
varices, risk factors for HCV infection, and estimated
duration of HCV infection (data not shown).
Discussion
This nested case-control study of HBsAg-negative
patients from the United States with advanced chronic
hepatitis C showed that neither previous (presence of
anti-HBc with or without anti-HBs in serum) nor
occult (detectable HBV DNA in liver) HBV infection
was associated with the development of HCC. In this
study, HBV DNA was detected in the livers of 11% of
patients with HCC and in 24% of matched controls
without HCC (HCC: OR 0.42, 95% CI 0.12-1.52;
P ¼ 0.18). In studies from Japan and Italy, the
reported frequency of HBV DNA detection in the
liver of HBsAg-negative, anti-HCV–positive patients
has ranged from 15%9 to 49%10 for patients without
HCC and up to 73% among patients with HCC.11
Most4,12-14 but not all9,15-17 studies from Asia and
Europe have found that patients with hepatitis C who
had detectable HBV DNA in the liver or serum had
an increased risk of HCC.
In the current study, 67% of HCC patients and
62% of matched controls with HBV DNA in the liver
had anti-HBc in serum, an indication of previous
Fig. 1. Prevalence of anti-HBc and anti-HBs in the sera of HCC
patients (n ¼ 91) and matched controls (n ¼ 182).
Table 2. HBV Markers in Serum and Liver of HCC Cases and Controls
HCC Cases Controls Odds Ratio 95% Confidence Interval P Value
HBV antibodies in serum n ¼ 91 n ¼ 182
Anti-HBc 53 (58%) 99 (54%) Ref.
Anti-HBcþ, anti-HBsþ/ 38 (42%) 83 (46%) 0.85 0.51-1.43 0.54
Anti-HBcþ, anti-HBs 15 (16%) 45 (25%) 0.63 0.33-1.12 0.12
Anti-HBcþ, anti-HBsþ 23 (25%) 38 (21%) 1.13 0.60-2.138 0.27
HBV DNA in liver n ¼ 28 n ¼ 55
HBV DNA 25 (89%) 42 (76%) Ref.
HBV DNAþ 3 (11%) 13 (24%) 0.42 0.12-1.52 0.18
Controls were matched 2:1 to cases for fibrosis strata on baseline biopsy, treatment assignment, and duration of follow-up. Matched odds ratios were deter-
mined by logistic regression analyses.
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HBV infection. Similarly, studies in Asia and Europe
found that most but not all patients with occult HBV
infection had markers of previous HBV infection in
the serum.4,10-13,18,19 HBV DNA was detected in the
liver of 32 of 57 anti-HBc–negative patients with
HCC in one study in Italy4 and in three of four anti-
HBc–negative patients with HCC in a study in Ja-
pan.11 Several mechanisms for occult HBV infection
have been proposed. First, patients with chronic HBV
infection who have undergone spontaneous loss of
HBsAg often have persistent HBV DNA in the liver.20
These patients are often positive for anti-HBc only.
Second, patients who have recovered from acute HBV
infection may have detectable HBV DNA in the liver
for many years after HBsAg to anti-HBs seroconver-
sion.21,22 These patients usually are anti-HBc–positive
and anti-HBs–positive. Third, patients might be
chronically infected with HBV variants with decreased
HBsAg production or altered HBsAg epitopes leading
to false negative results in standard enzyme immunoas-
says for HBsAg, although this situation appears to be
rare.23 These patients would be positive for anti-HBc.
Fourth, patients coinfected with other hepatitis viruses
such as HCV may have suppressed HBV replication as
a result of viral interference.24 Finally, some patients
may have primary occult HBV infection, i.e., low-dose
infection and only a partial induction or a total lack of
humoral immunity accounting for the absence not
only of HBsAg but also anti-HBc and anti-HBs.25,26
This phenomenon was first described in woodchucks25
and confirmed in humans.26 In the latter study, anti-
Fig. 2. Prevalence of HBV DNA in the livers of HCC patients (n ¼
28) and matched controls (n ¼ 55).
Table 3. Baseline Characteristics of Patients with and Without HBV Markers in Serum
Anti-HBc1 (n 5 121)
Anti-HBc2 (n 5 152) P Value*Anti-HBs2 (n 5 60) Anti-HBs1 (n 5 61)
Demographics
Age, years 50.4 (5.59) 51.8 (7.38) 51.1 (8.01) 0.96
Male sex 83.3% 73.8% 71.1% 0.16
Race 0.09
White 70.0% 60.7% 74.3%
Hispanic 5.0% 9.8% 10.5%
Black 23.3% 24.6% 13.8%
Other 1.7% 4.9% 1.3%
Laboratory tests
Platelets, 1,000/mm3 150.4 (53.5) 141.4 (47.1) 153.4 (66.7) 0.30
Albumin, g/dL 3.77 (0.44) 3.74 (0.39) 3.88 (0.44) 0.02
AST, U/L 110.2 (83.6) 91.6 (44.4) 96.1 (67.2) 0.57
ALT, U/L 126.8 (105.4) 110.2 (63.0) 114.1 (92.3) 0.69
Alkaline phosphatase, U/L 112.6 (65.4) 111.1 (54.4) 105.3 (48.0) 0.32
Total bilirubin, mg/dL 0.81 (0.35) 0.83 (0.34) 0.85 (0.46) 0.57
INR 1.07 (0.11) 1.06 (0.11) 1.05 (0.13) 0.17
AFP, ng/mL 19.0 (31.9) 23.4 (36.4) 16.8 (21.1) 0.20
Cirrhosis 60.0% 49.2% 56.6% 0.74
Maintenance peginterferon 44.1% 54.1% 42.3% 0.26
Esophageal varices 33.9% 33.3% 32.4% 0.84
Risk factors
Transfusion of blood or blood products 33.9% 32.8% 45.7% 0.04
Occupational exposure to human blood 23.3% 26.2% 23.8% 0.86
Tattoos 33.3% 41.0% 26.3% 0.054
Body piercing 0.0% 4.9% 0.0% 0.09
Recreational drug use 63.3% 52.5% 33.5% <0.0001
Cocaine use 73.3% 57.4% 46.1% 0.002
Data are expressed as the mean (SD) or as a percentage.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio.
*Comparison of 121 anti-HBcþ versus 152 anti-HBc patients.
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HBc–positive patients but not anti-HBc–negative
patients with occult HBV infection showed a T cell
response typical of protective memory.
Nearly half of the patients in this study had anti-
HBc in the serum, indicating they had been infected
with HBV in the past; however, the prevalence of anti-
HBc was not different between the HCC cases and
the controls: 42% versus 46% (HCC: OR 0.85; P ¼
0.54). Our results differ from the majority of studies
from Japan and Italy, which found that HBsAg-nega-
tive patients with chronic hepatitis C who were anti-
HBc–positive are at increased risk for HCC.17,27
Another difference between our findings and many
other studies is the low prevalence of HBV DNA in
serum. Only one of 273 patients tested had detectable
serum HBV DNA at a very low level and this was
observed in a control patient. By contrast, detection
rates of low-level DNA of up to 78% had been
reported in Asian studies.9,17,19,27 Although a higher
percentage of patients from Asia and southern Europe
were anti-HBc–positive, the difference in detection
rate of HBV DNA in serum between our study and
these studies cannot be explained by differences in
prevalence of anti-HBc. The lower rate of HBV DNA
detection in our patients who were anti-HBc–positive
may be related to the fact that most of the HALT-C
patients likely acquired HBV infection as adults and
cleared HBsAg after a transient infection, whereas
many of the anti-HBc–positive patients in Italy and Ja-
pan likely acquired HBV infection during childhood
and did not clear HBsAg until after many years of
chronic HBV infection. Several studies from Asia also
reported very low rates of HBV DNA detection in se-
rum (2%-11%), despite a high prevalence of anti-
HBc.17,19
Data on occult HBV infection and HCC in the
United States are limited. Hsia et al.28 found HBV
DNA in the livers of 17 of 31 (54.8%) HBsAg-nega-
tive North American patients with HCC; five of these
patients were infected with hepatitis C and seven were
anti-HBc–positive. Kannangai et al.29 detected HBV
DNA in the livers of three of 19 (16%) HBsAg-nega-
tive patients in the United States; only five of the 19
were infected with hepatitis C. Shetty et al.30 found
HBV DNA in the livers of 13 of 21 (62%) patients
with HCV-related HCC and 9 of 23 (39%) patients
with HCV-related cirrhosis and no HCC. An erratum
published by Shetty concluded that occult HBV was
not associated with HCC (P ¼ 0.36).31 Our study dif-
fers from these three studies in that very small samples
from liver biopsies rather than surgically resected
tumors or explant livers were available for testing for
HBV DNA. Moreover, the baseline biopsies from our
patients were obtained 0.3-9.1 years (median, 5.15
years) before the diagnosis of HCC was made, whereas
liver samples in the other studies were obtained at the
time of HCC diagnosis.
Our study differed from studies in Asia and Europe
in several additional respects. First, the prevalence of
chronic HBV infection is low in the United States
compared with Asia and southern Europe. Thus, the
likelihood of detecting markers of previous or occult
HBV infection in our patients would be expected to
be lower than in patients from Asia or southern
Europe. Nevertheless, we found HBV DNA in the liv-
ers in 19% and anti-HBc in the serum in 44% of our
patients. The relatively high prevalence of occult HBV
and previous HBV infection in a country with low en-
demicity is likely related to the shared risk factors for
hepatitis B and hepatitis C. In this study, the controls
were carefully matched to the HCC cases in having
similar stage of fibrosis on liver biopsy as well as com-
parable duration of follow-up with no HCC. In prior
studies, the frequency of HBV DNA detection
increased with more advanced liver fibrosis.16,18 Thus,
studies comparing patients with HCC with those with
less advanced fibrosis would be expected to show a
more marked difference in HBV DNA or anti-HBc
detection between the two groups. Indeed, some
HBsAg-negative patients with HBV DNA in the liver
or anti-HBc in the serum might have been chronically
infected with HBV for decades before spontaneous loss
of HBsAg, and the previous chronic HBV infection
may have contributed to increased risk of HCC as
well as increased risk of liver fibrosis. Several studies
have shown that the risk of HCC persists if HBsAg
clearance occurred after age 50 or after the develop-
ment of cirrhosis.20,32 HBV genotypes in our patients
and those in Europe or Asia may also be different.
Our study had several potential limitations. First,
the number of patients with HCC was relatively small.
Nonetheless, this is the largest such study in the
United States with 83 liver and 273 serum samples
from patients with chronic HCV infection. Second,
the liver tissue and serum samples had been stored for
up to 9 years before being tested. However, all the
samples had been stored at 70C and had not been
subjected to freezing/thawing previously. Although it is
possible that DNA may have been degraded during
long-term storage, serum antibodies should be robust,
and there is no reason to expect more rapid DNA deg-
radation in the samples from HCC patients than con-
trols. Third, only 2-3 mm of liver tissue was generally
available for HBV DNA detection. In many other
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studies, surgically resected HCC and/or surrounding
noncancerous liver tissue or explant liver were used for
HBV DNA detection. It is possible that the HBV
DNA detection rate may be higher if larger samples of
liver tissue were available, but the increase in yield
would have to be substantial for us to show a statisti-
cally significant difference between patients with or
without HCC. Fourth, PCR amplification of DNA
from liver samples was performed from only two
regions of the HBV genome in this study, and both
reactions must be positive for the sample to be consid-
ered as positive, whereas some of the prior studies per-
formed PCR reactions in three or four regions of the
HBV genome and considered samples with positive
results in two of three or two of four regions as posi-
tive. The likelihood that our method led to a gross
underdetection of HBV DNA in the liver is low,
because other studies have shown that HBV DNA
sequences are generally preserved, and HBV DNA
detection rate is similar with primers in different
regions of the HBV genome.3,4,33 Fifth, although the
HALT-C Trial is a prospective study, we performed a
case-control study and did not test stored serum and
liver samples from all patients in the study. However,
the nested case control study used here is an efficient
design that allows reasonable inference for the entire
HALT-C cohort. Sixth, frozen liver samples were avail-
able in only 31% of HCC cases, but there was no dif-
ference between HCC cases with and without liver
samples regarding demographics, severity of liver dis-
ease, fibrosis stage, treatment assignment, and risk fac-
tors for HCV infection. Finally, despite matching cases
and controls for baseline fibrosis stage, the HCC cases
were older and had laboratory values, suggesting more
advanced liver disease.
In conclusion, patients with HCC in the HALT-C
cohort did not have a higher rate of detection of anti-
HBc in serum or HBV DNA in liver compared with
matched controls with no HCC. Our data suggest that
neither previous nor occult HBV infection is an im-
portant factor in HCC development among patients
with histologically advanced chronic hepatitis C in the
United States.
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